Compare Ascendis Pharma A/S (ASND) vs Barrick Gold Corp (B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Barrick Gold Corp — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Barrick Gold Corp trades at $36.02 (market cap $61.25B). The key difference: Barrick Gold Corp is far larger — about 3.5× Ascendis Pharma A/S's market cap, and Barrick Gold Corp pays a 1.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | B | |
|---|---|---|
Market Cap | $17.74B | $61.25B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $52.97 |
52-Week Low | $163.32 | $20.73 |
Enterprise Value | $18.11B | $58.85B |
Dividend Yield | — | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Barrick Mining (B) trades at $36.68, down 0.41% on the day, with a bearish technical signal but strong fundamentals. The company reported robust 2025 results with revenue of $16.96B and net income of $4.99B, beating earnings estimates in recent quarters. Analyst consensus is strongly bullish with a $51.80 price target, though technical indicators show near-term weakness with support at $36.
The stock presents a value opportunity with a low P/E of 10.07 and strong cash flow growth, but faces headwinds from gold price volatility and bearish momentum. Upside potential exists if Q2 2026 earnings meet or exceed expectations, while risks include commodity price swings and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
